BTIG on Compass Pathways (CMPS): 'COMP360 is shaping up as clinically meaningful'
Tweet Send to a Friend
BTIG analyst Thomas Shrader reiterated a Buy rating and $14.00 price target on Compass Pathways (NASDAQ: CMPS)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
